Genetic Aberrations in Imatinib-Resistant Dermatofibrosarcoma Protuberans Revealed by Whole Genome Sequencing

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Hong, Jung Yong ^a   Liu, Xiao ^b,d   Mao, Mao ^c   Li, Miao ^b   Choi, Dong Il ^a   Kang, Shin Woo ^e   Lee, Jeeyun ^a   La Choi, Yoon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b BGI SHENZHEN   (China)

^c PFIZER INC   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DOXORUBICIN; IFOSFAMIDE; IMATINIB; PAZOPANIB; SUNITINIB;

ACAP2 GENE; ADULT; ARTICLE; CANCER GROWTH; CARD10 GENE; CASE REPORT; DERMATOFIBROSARCOMA PROTUBERANS; DRUG DOSE INCREASE; FEMALE; GENE DELETION; GENE DOSAGE; GENE INSERTION; GENE SEQUENCE; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; KIAA0556 GENE; KPAAQR7 GENE; LUNG METASTASIS; MENINGEAL METASTASIS; MUTATIONAL ANALYSIS; ONCOGENE; PPP1R39 GENE; SAFB2 GENE; SOMATIC MUTATION; STARD9 GENE; ZFYVE9 GENE;

BENZAMIDES; CARD SIGNALING ADAPTOR PROTEINS; CARRIER PROTEINS; DERMATOFIBROSARCOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; GTPASE-ACTIVATING PROTEINS; HUMANS; MATRIX ATTACHMENT REGION BINDING PROTEINS; MIDDLE AGED; NUCLEAR MATRIX-ASSOCIATED PROTEINS; PIPERAZINES; PYRIMIDINES; RECEPTORS, ESTROGEN;

EID: 84880772428     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069752     Document Type: Article

References (57)

1. Gloster HM Jr, (1996) Dermatofibrosarcoma protuberans. J Am Acad Dermatol 35: 355-374 quiz 375-356.
2. Criscione VD, Weinstock MA, (2007) Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 56: 968-973.
3. Rouhani P, Fletcher CD, Devesa SS, Toro JR, (2008) Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer 113: 616-627.
4. Chang CK, Jacobs IA, Salti GI, (2004) Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 30: 341-345.
5. Kimmel Z, Ratner D, Kim JY, Wayne JD, Rademaker AW, et al. (2007) Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data. Ann Surg Oncol 14: 2113-2120.
6. Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, et al. (2000) Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer 88: 2711-2720.
7. Sandberg AA, Bridge JA, (2003) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 140: 1-12.
8. Pedeutour F, Simon MP, Minoletti F, Barcelo G, Terrier-Lacombe MJ, et al. (1996) Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. Cytogenet Cell Genet 72: 171-174.
9. Simon MP, Navarro M, Roux D, Pouyssegur J, (2001) Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in Dermatofibrosarcoma protuberans (DP). Oncogene 20: 2965-2975.
10. Patel KU, Szabo SS, Hernandez VS, Prieto VG, Abruzzo LV, et al. (2008) Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 39: 184-193.
11. Shimizu A, O'Brien KP, Sjoblom T, Pietras K, Buchdunger E, et al. (1999) The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 59: 3719-3723.
12. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, et al. (2001) Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61: 5778-5783.
13. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR, (2002) Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100: 623-626.
14. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, et al. (2002) Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20: 3586-3591.
15. Labropoulos SV, Razis ED, (2007) Imatinib in the treatment of dermatofibrosarcoma protuberans. Biologics 1: 347-353.
16. Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED, (2005) Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 16: 461-466.
17. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, et al. (2005) Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23: 866-873.
18. Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, et al. (2010) Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 28: 1772-1779.
19. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, et al. (2012) VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22: 568-576.
20. Chiang DY, Getz G, Jaffe DB, O'Kelly MJ, Zhao X, et al. (2009) High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods 6: 99-103.
21. Miller SJ, Alam M, Andersen JS, Berg D, Bichakjian CK, et al. (2012) Dermatofibrosarcoma protuberans. J Natl Compr Canc Netw 10: 312-318.
22. Cribier B, Noacco G, Peltre B, Grosshans E, (2002) Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans. J Am Acad Dermatol 46: 408-413.
23. Kahn HJ, Fekete E, From L, (2001) Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa. Hum Pathol 32: 50-56.
24. Kim HJ, Lee JY, Kim SH, Seo YJ, Lee JH, et al. (2007) Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34. Br J Dermatol 157: 319-324.
25. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, et al. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349: 1423-1432.
26. Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, et al. (2003) Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17: 2401-2409.
27. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004.
28. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056.
29. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
30. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, et al. (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23: 1054-1061.
31. Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, et al. (2007) Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 13: 5398-5405.
32. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764-4774.
33. Deininger M, (2008) Resistance and relapse with imatinib in CML: causes and consequences. J Natl Compr Canc Netw 6 Suppl 2: S11-S21.
34. Corless CL, Heinrich MC, (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3: 557-586.
35. Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, et al. (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14: 352-359.
36. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551.
37. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, et al. (2009) Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113: 2154-2160.
38. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338.
39. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, et al. (2012) Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44: 760-764.
40. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, et al. (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101-105.
41. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058-1066.
42. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, et al. (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481: 506-510.
43. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, et al. (2008) Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322: 1377-1380.
44. Ding L, Ellis MJ, Li S, Larson DE, Chen K, et al. (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005.
45. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29: 3085-3096.
46. Shi H, Moriceau G, Kong X, Lee MK, Lee H, et al. (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3: 724.
47. Sun J, (2010) CARMA3: A novel scaffold protein in regulation of NF-kappaB activation and diseases. World J Biol Chem 1: 353-361.
48. Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, et al. (2011) CARMA3 is crucial for EGFR-Induced activation of NF-kappaB and tumor progression. Cancer Res 71: 2183-2192.
49. Crone SG, Jacobsen A, Federspiel B, Bardram L, Krogh A, et al. (2012) microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-kappaB by targeting CARD10 and COPS8 in gastric cancer. Mol Cancer 11: 71.
50. Li Z, Qu L, Dong Q, Huang B, Li H, et al. (2012) Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression. PLoS One 7: e36903.
51. Miao Z, Zhao T, Wang Z, Xu Y, Song Y, et al. (2012) CARMA3 is overexpressed in colon cancer and regulates NF-kappaB activity and cyclin D1 expression. Biochem Biophys Res Commun 425: 781-787.
52. Kohno T, Takakura S, Yamada T, Okamoto A, Tanaka T, et al. (1999) Alterations of the PPP1R3 gene in human cancer. Cancer Res 59: 4170-4174.
53. Ammerich-Hille S, Bardout VJ, Hilsenbeck SG, Osborne CK, Oesterreich S, (2010) Low SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Res Treat 121: 503-509.
54. Hong EA, Gautrey HL, Elliott DJ, Tyson-Capper AJ, (2012) SAFB1- and SAFB2-mediated transcriptional repression: relevance to cancer. Biochem Soc Trans 40: 826-830.
55. Bergman A, Abel F, Behboudi A, Yhr M, Mattsson J, et al. (2008) No germline mutations in supposed tumour suppressor genes SAFB1 and SAFB2 in familial breast cancer with linkage to 19p. BMC Med Genet 9: 108.
56. Torres JZ, Summers MK, Peterson D, Brauer MJ, Lee J, et al. (2011) The STARD9/Kif16a kinesin associates with mitotic microtubules and regulates spindle pole assembly. Cell 147: 1309-1323.
57. Torres JZ, (2012) STARD9/Kif16a is a novel mitotic kinesin and antimitotic target. Bioarchitecture 2: 19-22.